首页> 外文OA文献 >Donepezil Combined with Natural Hirudin Improves the Clinical Symptoms of Patients with Mild-to-Moderate Alzheimer's Disease: A 20-Week Open-Label Pilot Study
【2h】

Donepezil Combined with Natural Hirudin Improves the Clinical Symptoms of Patients with Mild-to-Moderate Alzheimer's Disease: A 20-Week Open-Label Pilot Study

机译:多奈哌齐联合天然水rud素可改善轻度至中度阿尔茨海默氏病患者的临床症状:一项为期20周的开放标签试验研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aim:To evaluate the efficacy and safety of donepezil plus natural hirudin in patients with mild-to-moderate Alzheimer's Disease. Methods: In the 20-week, randomized, open-label and controlled study, 84 patients received either donepezil (5 mg/day for the first 4 weeks and 10 mg/day thereafter) or donepezil plus natural hirudin (3 g/day) treatment. Efficacy was reflected by the change of the total scores of Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-Cog), Activities of Daily Life (ADL) and Neuropsychiatric Inventory (NPI). Results: The patients with the donepezil plus natural hirudin treatment showed more significant improvement in the daily activities and the decline of the cognition than those with donepezil treatment. Significant difference was present in the groups since the 8th week. No group difference was found in the NPI change. However, within the hirudin treatment group, more powerful efficacy including NPI assessment was found in the patients with vascular risk factors (VRF) as comparing to with those without VRF. The combination of donepezil and natural hirudin was well tolerated. The dropout rate was greater in the donepezil and natural hirudin (50%) treatment group than in the donepezil (39%) treatment group. Similar result was found in the incidence of adverse events (23.8% vs 19.0%), but there was no statistical difference between the two groups. Adverse events were the most common reason for the dropout. Although hemorrhage and hypersensitiveness were more common in donepezil plus Maixuekang treatment (11.9% and 7.1%) group than in donepezil treatment (2.4% and 2.4%) group, no significant difference was present between the two groups. Economic problem was another important reason for the patients' withdrawal. Conclusions: Compared with the donepezil treatment in the patients with mild-to-moderate AD, our results suggest that donepezil combined with natural hirudin may improve the treatment effects in the ADL, BPSD and cognition of the patients. Furthermore, this joint treatment is safe.
机译:目的:评估多奈哌齐联合天然水rud素在轻度至中度阿尔茨海默氏病患者中的疗效和安全性。方法:在为期20周的随机,开放标签和对照研究中,有84名患者接受多奈哌齐(头4周每天5 mg /天,此后10 mg /天)或多奈哌齐加天然水rud素(3 g /天)。治疗。阿尔茨海默氏病评估量表认知子量表(ADAS-Cog),日常生活活动量(ADL)和神经精神病学量表(NPI)总分的变化反映了疗效。结果:与多奈哌齐治疗相比,多奈哌齐联合天然水rud素治疗的患者的日常活动和认知能力下降更为明显。从第8周开始,各组之间存在显着差异。 NPI变化中未发现组差异。然而,在水rud素治疗组中,与无VRF的患者相比,具有血管危险因素(VRF)的患者发现了更强大的功效,包括NPI评估。多奈哌齐和天然水rud素的组合耐受性良好。多奈哌齐和天然水rud素(50%)治疗组的辍学率高于多奈哌齐(39%)治疗组。不良事件的发生率也相似(分别为23.8%和19.0%),但两组之间无统计学差异。不良事件是辍学的最常见原因。尽管多奈哌齐联合麦血康治疗组(11.9%和7.1%)的出血和过敏反应较多奈哌齐治疗(2.4%和2.4%)组更为常见,但两组之间无显着差异。经济问题是患者退出的另一个重要原因。结论:与多奈哌齐治疗轻度至中度AD患者相比,我们的结果表明多奈哌齐联合天然水rud素可改善ADL,BPSD的治疗效果和患者认知。此外,这种联合治疗是安全的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号